During the past decade, Stanford Univ School of Med; Oncology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Stanford Univ School of Med; Oncology" are "HER2-positive Breast Cancer" (1 trials) and "Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Stanford Univ School of Med; Oncology" in a lesser frequency.

Most popular intervention types in "Stanford Univ School of Med; Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials), "Nab-Paclitaxel" (1 trials), "Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Stanford Univ School of Med; Oncology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Stanford Univ School of Med; Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Stanford Univ School of Med; Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Stanford Univ School of Med; Oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".